SAN
DIEGO, June 21, 2024 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused
on developing products to treat cancer and life threatening
infectious diseases, today announced that it will issue financial
results for its fiscal year ended March 31,
2024, at 4:15 p.m. ET on
Thursday, June 27, 2024.
Management will host a conference call on
Thursday, June 27, 2024, at
4:30 p.m. ET to review financial
results and recent corporate developments. Following management's
formal remarks, there will be a question and answer session.
Interested parties can register for the
conference by navigating to
https://dpregister.com/sreg/10190237/fce977aef1. Please note that
registered participants will receive their dial-in number upon
registration.
Interested parties without internet access or
unable to pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE):
1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the Aethlon Medical,
Inc. conference call.
A replay of the call will be available
approximately one hour after the end of the call through
July 27, 2024. The replay can be
accessed via Aethlon Medical's website or by dialing 1-877-344-7529
(domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay
conference ID number is 6876352.
About Aethlon and the
Hemopurifier®
Aethlon Medical is a medical
therapeutic company focused on developing the Hemopurifier, a
clinical stage immunotherapeutic device which is designed to combat
cancer and life-threatening viral infections and for use in organ
transplantation. In human studies, the Hemopurifier has
demonstrated the removal of life-threatening viruses and in
pre-clinical studies, the Hemopurifier has demonstrated the removal
of harmful exosomes from biological fluids, utilizing its
proprietary lectin-based technology. This action has potential
applications in cancer, where exosomes may promote immune
suppression and metastasis, and in life-threatening infectious
diseases. The Hemopurifier is a U.S. Food and Drug Administration
(FDA) designated Breakthrough Device indicated for the treatment of
individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in
the development or severity of the disease. The Hemopurifier also
holds an FDA Breakthrough Device designation and an open
Investigational Device Exemption (IDE) application related to the
treatment of life-threatening viruses that are not addressed with
approved therapies.
Additional information can be found at
www.AethlonMedical.com.
Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
View original
content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-fiscal-year-end-financial-results-and-host-conference-call-on-june-27-2024-302178802.html
SOURCE Aethlon Medical, Inc.